Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04762017 | OCS-05 in Patients With Optic Neuritis | PHASE2 | COMPLETED | 36 | — | — | Feb 1, 2021 | Sep 1, 2024 | Sep 21, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| OCS-05 +SoC (corticosteroid) IV administration | DRUG | OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days |
| Placebo + SoC (corticosteroid) IV administration | OTHER | Placebo + SoC (corticosteroid) IV administration for 5 consecutive days |